Understanding HCV Reinfection Rates in an Incarcerated Population After

Clinical Trial Summary

This pilot study is crucial to determining whether treating individuals who are at high risk for transmission or re-infection will impact HCV reinfection rates. It will establish the feasibility of DAA treatment in corrections facilities, as well as delineate the underlying immune basis of HCV cure and reinfection.

See also
Status	Clinical Trial	Phase
Completed	`NCT02907996` - Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
Completed	`NCT02207088` - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease	Phase 3
Not yet recruiting	`NCT02893046` - HCV Care Pathway in Ile-de-France	N/A
Completed	`NCT01428063` - Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials	Phase 2
Completed	`NCT01396005` - A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)	Phase 1
Completed	`NCT01195181` - Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.	Phase 4
Completed	`NCT00219999` - Hepatitis C Virus and the Humoral Immune System	N/A
Completed	`NCT02243293` - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection	Phase 2/Phase 3
Completed	`NCT02265237` - A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)	Phase 3
Not yet recruiting	`NCT06104046` - Prevalence of Seroconversion of Hepatitis c Virus Among Children With CKD on Regular Hemodialysis
Completed	`NCT02604017` - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection	Phase 3
Withdrawn	`NCT00947245` - Japanese Bridging Study Conducted in the United States	Phase 1
Completed	`NCT01713283` - Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection	Phase 2
Completed	`NCT01479881` - A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus	Phase 1
Completed	`NCT01458535` - A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)	Phase 2
Completed	`NCT01193361` - Ph IIA Study (SOC +/- NS5B)	Phase 2
Completed	`NCT01241773` - TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir	Phase 1
Completed	`NCT01006031` - Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4	Phase 2/Phase 3
Completed	`NCT00819026` - Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors	N/A
Completed	`NCT00382798` - Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin	Phase 1/Phase 2

NCT number	NCT02460133
Study type	Interventional
Source	Nova Scotia Health Authority
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	July 2015
Completion date	October 2023

Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms